News & Insights

LOS ANGELES--(BUSINESS WIRE)--SpineX Inc. is today announcing close to full recruitment -- over 80% -- of the patient cohort for its clinical trial of its proprietary SCONE™ device. SCONE is an innovative device that treats urinary incontinence allowing people living with neurogenic bladder due to spinal cord injury, multiple sclerosis, or stroke to live life on their own terms. The clinical trial—Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE “CONTINENCE” Cl

LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Reports Positive Results from Phase 4 Trial of VTAMA® (tapinarof) Cream, 1% for Treatment of Plaque Psoriasis in the Head and Neck Region

IRVINE, Calif.--(BUSINESS WIRE)-- #Breakthrough--CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive NMIBC

LOS ANGELES--(BUSINESS WIRE)-- #calderamedical--Caldera Medical, a leader in women’s health solutions, is proud to announce the appointment of John Pitstick as its new Chief Financial Officer & EVP Corporate Development. With a strategic focus on advancing Caldera Medical's position in the women’s health sector, Caldera Medical completed its acquisition of Atlantic Therapeutics based in Galway Ireland on September 1st of this year and maintains an innovation and operations team in Ireland as its European hea

OXFORD, England & IRVINE, Calif. & PASADENA, Calif.--(BUSINESS WIRE)--Rockley Photonics begins sampling the Bioptx™ Biosensing band and platform for continuous, non-invasive monitoring of spectroscopy-based biomarkers

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Lilian Zhou to its Board of Directors, effective December 4, 2023. “We welcome Lilian Zhou as a new member to our Board of Directors. Lilian is an accomplished investment portfolio manager who worked at highly regarded Wall Street investment in

VALENCIA, Calif.--(BUSINESS WIRE)-- #cochlearimplant--Advanced Bionics (AB), a global leader in cochlear implant technology, received FDA approval and announces expansion of Marvel CI product and feature offerings to improve hearing care delivery and patient outcomes, including: Remote Programming via patient’s smartphone using AB Remote Support app, making hearing care more accessible for cochlear implant (CI) patients Linked two-ear solutions including with a CROS device, allowing more CI patients to hear well

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 27,000 restricted stock units of Atara’s common stock to three newly hired employees. These awards were approved by the Compensation Committee of Atara’s Board of Directors and granted under the

IRVINE, Calif.--(BUSINESS WIRE)-- #SUO2023--Cretostimogene Grenadenorepvec Monotherapy First Results Show 75.7% Complete Response Rate at Any Time in Patients w/High-Risk BCG-Unresponsive NMIBC

WEST HILLS, Calif. & HARRISON, N.Y.--(BUSINESS WIRE)--Pharmavite LLC, the leading nutrition powered wellness company and makers of Nature Made® vitamins, today announces its acquisition of Bonafide Health, the women’s health company creating a new standard in managing the journey of menopause. This is the continuation of Pharmavite’s ongoing commitment to bring the gift of health to life for all – including historically underserved categories. Through the acquisition of Bonafide Health, Pharmav

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, shares results from a new breakthrough study analyzing the safety of high-dose nicotinamide riboside (NR) supplementation on individuals with Parkinson’s disease (PD). This study was part of the ChromaDex External Research Program (CERP™), which donated ChromaDex’s patented NR ingredient, Niagen®, the most efficient and high quality NAD+ precurs

IRVINE, Calif.--(BUSINESS WIRE)--Bright Uro Announces $23M Series A Funding Round Led by Laborie – Expands Senior Leadership Team to Accelerate Next Phase of Commercialization

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced positive new data for tabelecleucel (tab-cel® or EBVALLO™) in patients with relapsed or refractory (r/r) or treatment-naïve Epstein-Barr virus-positive post-transplant lymphoproliferative disease involving

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2023. The company is hosting a conference call today, November 29, 2023, at 4:30 p.m. ET to discuss the results. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. A replay of the webcast will be available approximately two hours after the co

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--BrainChip Details Olfactory Capabilities of Identifying Bacteria in the Blood in New Research Report

IRVINE, Calif.--(BUSINESS WIRE)--ReValve Solutions Inc. (ReValve), which has developed a next generation technology for Transcatheter Mitral Valve Replacement (TMVR), announced that an 81-year-old male, with a history of heart failure, a series of failed surgical by-pass grafts and severe mitral regurgitation (MR 4+), was successfully treated with the Palmetto System. The next generation TMVR procedure was performed using ReValve’s Palmetto System on October 11, 2023, at the Punta Pacifica Hosp

HUNTINGTON BEACH, Calif. & GOLD COAST, Australia & HOUSTON--(BUSINESS WIRE)--BiVACOR receives FDA approval with investigational device exemption to conduct early feasibility studies of its Total Artificial Heart

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-DM1, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy. ARO-DM1 is designed to reduce expression of the dystrophia myotonica protein kinase (DMPK) gene. There is curre

LOS ANGELES--(BUSINESS WIRE)-- #COVID19--Following the Associated Press reporting that the World Health Organization requested that China provide more data on a “potentially worrying spike in respiratory illnesses and clusters of pneumonia in children” publicly, AIDS Healthcare Foundation expresses concern today and urges China to be transparent and cooperate with the WHO unequivocally. “China has a history of a lack of disclosure of pertinent epidemiological data dating back to the SARS outbreak in 2002

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 9:30 am ET. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (Nasdaq: MASI) is a global technology company that develops and produces a wide array of industry-le

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 10:50 a.m. EST. A live

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. (NYSE: SONX) (“Sonendo” or the “Company”), a leading dental technology company and developer of the GentleWave® System, today announced that, on November 15, 2023, it received a notice from the New York Stock Exchange (the “NYSE”) that the Company was no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual (“Section 802.01B”) due to the Company’s average global market

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today announced that company management will present at the Piper Sandler 35th Annual Healthcare Conference in New York City on Tuesday, November 28, 2023, at 8:00 a.m. ET / 11:00 a.m. PT. A live webcast of the presentation will be available under "Events & Presentations" in

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in a fireside chat at the upcoming Piper Sandler 35th Annual Healthcare Conference on November 30, 2023, at 1:00 p.m. ET. A webcast of the presentation may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseas

IRVINE, Calif.--(BUSINESS WIRE)--The Masimo W1™ medical watch has received FDA 510(k) clearance for over-the-counter and prescription use.

LOS ANGELES--(BUSINESS WIRE)-- #MedTechInnovator--MedTech Innovator (MTI), the world’s largest accelerator of medical devices, today announced that MicroTransponder won the inaugural 2023 Mid-Stage Grand Prize competition, and Mirai Medical won the 2023 Value Award during the MedTech Strategist Innovation Summit in San Francisco. MicroTransponder received $200,000 in non-dilutive cash proceeds as the Mid-Stage Grand Prize winner, and Mirai Medical received $25,000 as the Value Award winner after receiving the high

MIAMI & ALISO VIEJO, Calif.--(BUSINESS WIRE)-- #microvention--MicroVention Celebrates 10-Year Anniversary and Legacy of SOFIA™ Aspiration Catheters

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the company will be participating in the 35th Annual Piper Sandler Healthcare Conference, which is taking place in New York City, November 28-30, 2023. Details of the presentation can be found below. Piper Sandler Healthcare Conference Date     Thursday, November 30, 2023 Time:     10:30 am EST Format:     Fireside chat with Director and Senior Research Analyst Jo

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ Endoscopy-America, Inc., a supplier of surgical endoscopy equipment and related medical systems, is featured on the latest episode of “Military Makeover: Operation Career.” The series shares stories of military veterans who have successfully transitioned to civilian life by finding meaningful and rewarding career opportunities. KARL STORZ is home to numerous veterans—not to mention active reservists. The TV program highlights three former service

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced that management will participate in the Stephens Annual Investment Conference on Thursday, November 16, 2023. Management will participate in a Fireside Chat on Thursday, November 16, 2023, at 6 a.m. PT / 8 a.m. CT. The Fireside chat will we be webcast live at the

SANTA MONICA, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced that the companies have expanded their existing collaboration, which was originally announced in December 2022. Kite has exercised its option to negotiate a license for Arcellx’s ARC-SparX program, ACLX-001, in multiple myeloma, which is comprised of ARC-T cells and SparX proteins that target BCMA. The companies have also expanded the scope of th

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that members of its management team are scheduled to participate in the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023. These representatives of the company will conduct a presentation beginning at approximately 12:00 p.m. Easter

IRVINE, Calif.--(BUSINESS WIRE)-- #SUO2023--CG Oncology Announces Presentation of Interim Ph3 Monotherapy Data for Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC Patients at SUO 2023

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host a virtual investor day today, Nov. 14, 2023, starting at 1:00 pm ET, with presentations by the Company's leadership team.

IRVINE, Calif.--(BUSINESS WIRE)--Viseon, Inc. Announces First Cranial Tumor Resection Procedure Enabled by MaxView® 4K Advanced Digital Visualization

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented new Phase 2 clinical data from the ongoing SHASTA-2 and MUIR studies of plozasiran (ARO-APOC3) and the ARCHES-2 study of zodasiran (ARO-ANG3) at the American Heart Association (AHA) Scientific Sessions 2023, being held in Philadelphia, PA, on November 11-13, 2023. “The compelling data presented today at AHA support the further development of plozasiran in Phase 3 studies, including in patients with

EL SEGUNDO, Calif.--(BUSINESS WIRE)--Radiology Partners (RP), a leading radiology practice in the U.S. through its owned and affiliated practices, is proud to announce a significant achievement for the radiology specialty through the integration of artificial intelligence (AI) at unprecedented scale. By deploying AI across more than 20 million annual exams already this calendar year, RP’s investment in advancing and expanding AI demonstrates its commitment to elevating patient care, enhancing o

LONG BEACH, Calif.--(BUSINESS WIRE)--LA Times Awards AHF’s Out of the Closet Best Charity

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in October of non-qualified stock options to purchase an aggregate of 63,703 shares of Evolus and an aggregate of 70,320 restricted stock units (RSUs) of the company’s common stock to 8 newly hired non-executive employees of the company (the “October Grants”). The Company also is reporting the grant in Nove

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Healthcare Conference in New York on Tuesday, November 14, 2023 at 8:30 a.m. PST / 11:30 a.m. ES

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ Endoscopy-America, Inc., a supplier of surgical endoscopy equipment and related medical systems, is proud to appear on the 2023 Military Times Best for Vets: Employers list. Now in its 14th year, the Military Times Best for Vets: Employers list is based on the results of a voluntary survey that asks companies about their policies, practices, and benefits for veterans and their families. The survey captures the areas of greatest importance to veter

LOS ANGELES--(BUSINESS WIRE)--SpineX Inc., a clinical stage bioelectric medtech company, has had an important publication accepted in the prestigious Journal of Urology. The publication, entitled A Pilot Study of the Effect of Transcutaneous Spinal Cord Stimulation on Micturition-Related Brain Activity and Lower Urinary Tract Symptoms after Stroke shows improved bladder function and restoration of brain activity associated with normal voiding in stroke survivors who completed SpineX SCONE™ ther

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the Jefferies London Healthcare Conference on Wednesday, November 15, 2023 at 3:00 pm GMT. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (Nasdaq: MASI) is a global technology company that develops and produces a wide array of industry-leading mo

IRVINE, Calif.--(BUSINESS WIRE)--Today, PatientFi, the company behind aesthetics membership platform PRIVI, announces a collaboration with Galderma to provide aesthetic practices with a first-of-its-kind offering to give patients access to a convenient monthly membership to pay for custom treatment plans with Galderma’s portfolio of innovative aesthetic products, all while earning patient loyalty points through ASPIRE Galderma Rewards. With cost as the biggest barrier to treatment, Galderma and

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corporation (NASDAQ: CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, November 14, 2023, at 2:00 PM EDT. ChromaDex welcomes stakeholders, investors, and other individual followers to register and attend these live events. The

IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced today that the company will be presenting in two upcoming healthcare conferences: The 2023 Stifel Healthcare Conference Wednesday, November 15, 2023, at 10:55 AM Eastern Time. Canaccord Genuity Medical Technology and Diagnostics Forum Thursday, November 16, 2023, at 9:30 AM Eastern Time. About

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced primary analysis data from its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis (PMS). The study did not meet the primary endpoint of confirmed disability improvement (CDI) by exp

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. (“Sonendo”), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights Total revenue of $10.4 million for the third quarter of 2023, representing growth of 6%, compared to prior year period Reduced cash burn to approximately $10 million in the third quarter of 2023; additionally, implemented reduction in force in November 2023

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC) today announced financial results for the third quarter of 2023. Third Quarter 2023 and Recent Highlights Total net sales were $19.5 million, with $17.4 million from Tru Niagen®, up 14% and 19% from the prior year quarter, respectively. Strong gross margin of 61.4%, an increase of 160 basis points, compared to 59.8% from the prior year quarter. Sales and marketing expense as a percentage of net sales was 31.0%, an improvement of 340 b

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Wave Neuroscience announced today the receipt of a generous $1.5 million grant from the Engelstad Foundation that will support Wave Neuroscience’s Phase Two clinical trial currently underway with Texas A&M University Health Science Center (Texas A&M Health) Institute of Biosciences and Technology. This significant contribution will accelerate the trial, which aims to develop and validate innovative treatments for Post-Traumatic Stress Disorder (PT